Global Pulmonary Arterial Hypertension (PAH) Medicine Market Insights, Forecast to 2025

Table of Contents

1 Pulmonary Arterial Hypertension (PAH) Medicine Market Overview

• 1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Medicine
• 1.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type
  • 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate Comparison by Type (2021-2026)
  • 1.2.2 Calcium Channel Blockers
  • 1.2.3 Novel Targeted Drugs
  • 1.2.4 Other
• 1.3 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application
  • 1.3.1 Pulmonary Arterial Hypertension (PAH) Medicine Sales Comparison by Application: 2020 VS 2026
  • 1.3.2 Secondary Pulmonary Hypertension (SPH)
  • 1.3.3 Primary Pulmonary Hypertension (PPH)
• 1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Estimates and Forecasts
  • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2015-2026
  • 1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales 2015-2026
  • 1.4.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region: 2020 Versus 2026

2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competition by Manufacturers

• 2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2015-2020)
• 2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers (2015-2020)
• 2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Manufacturers (2015-2020)
• 2.4 Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Sites, Area Served, Product Type
• 2.5 Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation and Trends
  • 2.5.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Rate
  • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
  • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
• 2.7 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Medicine Players (Opinion Leaders)

3 Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario by Region

• 3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario in Sales by Region: 2015-2020
• 3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario in Revenue by Region: 2015-2020
• 3.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
  • 3.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.3.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
  • 3.4.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.4.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region
  • 3.5.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
  • 3.6.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.6.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.6.3 Mexico
  • 3.6.3 Brazil
  • 3.6.3 Argentina
• 3.7 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.7.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Analysis by Type

• 4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2015-2020)
• 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2015-2020)
• 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price Market Share by Type (2015-2020)
• 4.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Analysis by Application

• 5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2015-2020)
• 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2015-2020)
• 5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2015-2020)

6 Company Profiles and Key Figures in Pulmonary Arterial Hypertension (PAH) Medicine Business

• 6.1 Pfizer
  • 6.1.1 Corporation Information
  • 6.1.2 Pfizer Description, Business Overview and Total Revenue
  • 6.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2015-2020)
  • 6.1.4 Pfizer Products Offered
  • 6.1.5 Pfizer Recent Development
• 6.2 Gilead Sciences
  • 6.2.1 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
  • 6.2.2 Gilead Sciences Description, Business Overview and Total Revenue
  • 6.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2015-2020)
  • 6.2.4 Gilead Sciences Products Offered
  • 6.2.5 Gilead Sciences Recent Development
• 6.3 Eli Lilly
  • 6.3.1 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
  • 6.3.2 Eli Lilly Description, Business Overview and Total Revenue
  • 6.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2015-2020)
  • 6.3.4 Eli Lilly Products Offered
  • 6.3.5 Eli Lilly Recent Development
• 6.4 Actelion Pharmaceuticals
  • 6.4.1 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
  • 6.4.2 Actelion Pharmaceuticals Description, Business Overview and Total Revenue
  • 6.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2015-2020)
  • 6.4.4 Actelion Pharmaceuticals Products Offered
  • 6.4.5 Actelion Pharmaceuticals Recent Development
• 6.5 United Therapeutics Corporation
  • 6.5.1 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Production Sites and Area Served
  • 6.5.2 United Therapeutics Corporation Description, Business Overview and Total Revenue
  • 6.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2015-2020)
  • 6.5.4 United Therapeutics Corporation Products Offered
  • 6.5.5 United Therapeutics Corporation Recent Development

7 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Cost Analysis

• 7.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Raw Materials Price Trend
  • 7.1.3 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
• 7.4 Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors List
• 8.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers

9 Market Dynamics

• 9.1 Market Trends
• 9.2 Opportunities and Drivers
• 9.3 Challenges
• 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

• 10.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2021-2026)
  • 10.1.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2021-2026)
• 10.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2021-2026)
  • 10.2.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2021-2026)
• 10.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Region (2021-2026)
  • 10.3.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Region (2021-2026)
• 10.4 North America Pulmonary Arterial Hypertension (PAH) Medicine Estimates and Projections (2021-2026)
• 10.5 Europe Pulmonary Arterial Hypertension (PAH) Medicine Estimates and Projections (2021-2026)
• 10.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Estimates and Projections (2021-2026)
• 10.7 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Estimates and Projections (2021-2026)
• 10.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Estimates and Projections (2021-2026)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List